Compound probiotic anti-inflammatory oral liquid containing dictyophora indusiata and preparation method of compound probiotic anti-inflammatory oral liquid

Abstract

The invention relates to anti-inflammatory pediococcus acidilactici, the name of the pediococcus acidilactici is HA02018, the classification name of the pediococcus acidilactici is pediococcus acidilactici, the preservation number of the pediococcus acidilactici is CGMCC No.16658, the preservation date of the pediococcus acidilactici is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the preservation unit of the pediococcus acidilactici is China General Microbiological Culture Collection Center. The strain has an anti-inflammatory function; in addition, a bamboo fungus-containing composite probiotic anti-inflammatory oral liquid is prepared by applying the bacterial strain, the invention provides a formula of the bamboo fungus-containing composite pediococcus acidilactici anti-inflammatory oral liquid, the preservation property of the bamboo fungus-containing composite probiotic anti-inflammatory oral liquid can be well improved, and the anti-inflammatory effects of the bamboo fungus and probiotics can be effectively combined, so that the anti-inflammatory effect of the bamboo fungus-containing composite probiotic anti-inflammatory oral liquid is improved, and the anti-inflammatory effect of the bamboo fungus-containing composite probiotic anti-inflammatory oral liquid is improved. And the anti-inflammatory effect can be better exerted. The inherent eating mode of the bamboo fungus is changed, and the problem that the bamboo fungus is difficult to store, store and transport is solved. And the feed has a very wide probiotic prospect.

Description

Technical Field

[0001] The present invention mainly relates to the technical field of food, and particularly relates to a compound Pediococcus acidilactici anti-inflammatory oral liquid containing dictyophora indusiata and its formulation. Background Art

[0002] Dictyophora indusiata is a cryptogamic fungus parasitizing on the roots of withered bamboos and has been listed as one of the "eight treasures of grass" since ancient times. At present, research results show that dictyophora indusiata has various pharmacological effects such as anti-tumor, anti-radiation, antibacterial and anti-inflammatory, and enhancing the immune function of the body. Dictyophora indusiata has a special anti-corrosion, bacteriostatic and anti-inflammatory effect, which has been proved by many experiments. It has been found that the extract of dictyophora indusiata has strong bacteriostatic properties, and the bacteriostatic components are very stable at high temperatures and will not degrade when heated. There are also experiments showing that the extracts of dictyophora indusiata extracted by various extraction methods have significant bacteriostatic effects on yeasts, penicillium, and bacteria.

[0003] Due to the relatively strict requirements for the cultivation conditions of dictyophora indusiata, its poor stress resistance, high requirements for cultivation techniques, difficulty in storage, and large cultivation risks caused by storage and transportation, there has been a serious problem of too short harvesting period. And in the existing relevant reports, the experimental results show that the anti-inflammatory effect of the extract of dictyophora indusiata is not significant. Therefore, compounding a probiotic with anti-inflammatory effect and the extract of dictyophora indusiata and processing it into a beverage for market can not only greatly increase its preservation property, but also effectively combine the anti-inflammatory effects of dictyophora indusiata and the probiotic, so that the anti-inflammatory effect can be better exerted.

[0004] Existing research has confirmed that lactic acid bacteria produce various biological activities such as anti-inflammatory, immune regulation, antioxidant, and anti-tumor. At the same time, it has basically no cytotoxicity, making it one of the research hotspots in the fields of food science, natural medicine, etc., and having broad application prospects. The enhancement of immunity by lactic acid bacteria preparations is manifested in two aspects: one is to affect the non-specific immune response, enhance the vitality of mononuclear phagocytes and polymorphonuclear leukocytes, and stimulate the secretion of reactive oxygen species, lysosomal enzymes and monokines; the other is to stimulate the specific immune response, such as strengthening the levels of immunoglobulins such as IgA, IgM, and IgG on the mucosal surface and in the serum, strengthening humoral immunity, promoting the proliferation of T lymphocytes and B lymphocytes, and strengthening cellular immunity.

[0005] Pediococcus acidilactici can produce acid and beneficial metabolites, activate the activity of acid protease, participate in the body's metabolism, regulate the gastrointestinal flora, and maintain the balance of the intestinal microecosystem. There are already some invention patents and patent applications in China regarding the beneficial functions of Pediococcus acidilactici. CN 111849805 A discloses Pediococcus acidilactici HAO2018, which has the effect of anti-cervical cancer; CN 109182225 B discloses Pediococcus acidilactici AS185, which has the effect of anti-atherosclerosis. However, there is still little research on whether Pediococcus acidilactici has anti-inflammatory effects.

[0006] Currently, there are already some invention patents and patent applications in China regarding the anti-inflammatory effects of lactic acid bacteria. CN 110257287 A discloses Bacillus subtilis ZY10, which has the effects of anti-allergy and anti-dermatitis; CN 111281895 A discloses Lactobacillus plantarum ZJ316, which can treat colitis safely, effectively, and with few side effects. However, there has been no relevant report on Pediococcus acidilactici with clear anti-inflammatory ability before.

[0007] In summary, this patent has found a Pediococcus acidilactici with anti-inflammatory effects and prepared a compound Pediococcus acidilactici anti-inflammatory oral liquid containing dictyophora, which has very important research significance and economic value.

[0008] No patent publication documents related to this invention patent application were found through retrieval. Summary of the Invention

[0009] The purpose of the present invention is to address the difficulties in storing dictyophora and the unclear anti-inflammatory effects. It provides a compound probiotic anti-inflammatory oral liquid containing dictyophora and its formula.

[0010] To achieve the above objectives, the following technical solutions are adopted by us:

[0011] A Pediococcus acidilactici with anti-inflammatory effects, the name of the Pediococcus acidilactici is HAO2018, the classification name is Pediococcus acidilactici, the preservation number is: CGMCC No. 16658, the preservation date is October 30, 2018, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the preservation unit is the General Microbiology Center of the China Microbial Culture Collection Center.

[0012] Moreover, the Pediococcus acidilactici has strong acid tolerance

[0013] Moreover, the Pediococcus acidilactici has strong bile salt tolerance ability;

[0014] Moreover, the Pediococcus acidilactici has anti-inflammatory ability. An in vitro verification model was constructed by inducing excessive synthesis of nitric oxide (NO) in mouse RAW264.7 macrophages by cell lipopolysaccharide (LPS). The NO production inhibition rates of the supernatant and cell lysate of the strain fermentation broth at 5 mg / mL reached 60% and 56% respectively, verifying that the supernatant and cell lysate of the Pediococcus acidilactici fermentation broth can inhibit the level of NO.

[0015] Moreover, a compound probiotic anti-inflammatory oral liquid containing Dictyophora indusiata comprises the following components in parts by weight:

[0016] Dictyophora indusiata 45 - 50, fructose 5 - 10, honey 2 - 5, citric acid 0.1 - 0.5, carrageenan 0.1 - 0.15, pectinase 0.08 - 0.2, sterilized water 450 - 500.

[0017] In the production process of the above-mentioned compound probiotic anti-inflammatory oral liquid containing Dictyophora indusiata, inoculate 3% of Pediococcus acidilactici on the basis of the above method, and then ferment at 37 °C for 8 h.

[0018] In the production process of the above-mentioned compound probiotic anti-inflammatory oral liquid containing Dictyophora indusiata, the optimal weight distribution ratio is 47 of Dictyophora indusiata, 8 of fructose, 3 of honey, 0.3 of citric acid, 0.12 of carrageenan, 0.15 of pectinase, and 470 of water per portion of oral liquid.

[0019] In the production process of the above-mentioned compound probiotic anti-inflammatory oral liquid containing Dictyophora indusiata, the finally prepared compound probiotic anti-inflammatory oral liquid containing Dictyophora indusiata is refrigerated in a refrigerator at 0 - 4 °C, and the shelf life of the product at 0 - 4 °C is 14 days.

[0020] Moreover, the compound probiotic anti-inflammatory oral liquid containing Dictyophora indusiata and Pediococcus acidilactici has stronger anti-inflammatory ability than the Dictyophora indusiata oral liquid without probiotic fermentation. An in vitro verification model was constructed by inducing excessive synthesis of nitric oxide (NO) in mouse RAW264.7 macrophages by cell lipopolysaccharide (LPS). The NO production inhibition rate of the anti-inflammatory oral liquid reached 61%, verifying that the compound probiotic anti-inflammatory oral liquid containing Dictyophora indusiata can inhibit the level of NO.

[0021] The advantages and positive effects obtained by the present invention are as follows: mainly anti-inflammatory

[0022] 1. In the present invention, Pediococcus acidilactici has an anti-inflammatory function. An in vitro verification model was constructed by inducing excessive synthesis of nitric oxide (NO) in mouse RAW264.7 macrophages with cell lipopolysaccharide (LPS). The NO production inhibition rates of the supernatant of the strain fermentation broth and the cell lysate at 5 mg / mL were 60% and 56% respectively, verifying that the supernatant of the Pediococcus acidilactici fermentation broth and the cell lysate can inhibit the level of NO.

[0023] 2. In the present invention, the anti-inflammatory oral liquid containing Dictyophora indusiata and Pediococcus acidilactici has stronger anti-inflammatory ability than the Dictyophora indusiata oral liquid without probiotic fermentation. An in vitro verification model was constructed by inducing excessive synthesis of nitric oxide (NO) in mouse RAW264.7 macrophages with cell lipopolysaccharide (LPS). The NO production inhibition rate of the anti-inflammatory oral liquid reached 61%, verifying that the anti-inflammatory oral liquid containing Dictyophora indusiata and probiotics can inhibit the level of NO.

[0024] 3. An anti-inflammatory oral liquid containing Dictyophora indusiata and Pediococcus acidilactici has changed the inherent eating method of Dictyophora indusiata, and solved the problems of its difficult storage, storage and transportation. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 It is the acid tolerance graph of Pediococcus acidilactici HAO2018;

[0026] Figure 2 It is the bile salt tolerance graph of Pediococcus acidilactici HAO2018;

[0027] Figure 3 It is the influence of the supernatant of the fermentation broth of Pediococcus acidilactici HAO2018 in the present invention on the concentration of nitric oxide (NO) in the culture medium of mouse RAW264.7 macrophages;

[0028] Figure 4 It is the inhibition rate of the supernatant of the fermentation broth of Pediococcus acidilactici HAO2018 in the present invention on the production of nitric oxide (NO) in the culture medium of mouse RAW264.7 macrophages

[0029] Figure 5 It is the influence of the cell lysate of Pediococcus acidilactici HAO2018 in the present invention on the concentration of nitric oxide (NO) in the culture medium of mouse RAW264.7 macrophages.

[0030] Figure 6 It is the inhibition rate of the cell lysate of Pediococcus acidilactici HAO2018 in the present invention on the production of nitric oxide (NO) in the culture medium of mouse RAW264.7 macrophages

[0031] Figure 7 It is the influence of the anti-inflammatory oral liquid containing Dictyophora indusiata and Pediococcus acidilactici in the present invention on the concentration of nitric oxide (NO) in the culture medium of mouse RAW264.7 macrophages.

[0032] Figure 8 In the present invention, the inhibitory rate of the anti-inflammatory oral liquid containing Dictyophora indusiata and Pediococcus acidilactici on the production of nitric oxide (NO) in the culture medium of mouse RAW264.7 macrophages Detailed implementation manners

[0033] The present invention will be further described in detail below in conjunction with specific embodiments. The following embodiments are only descriptive and not restrictive, and the protection scope of the present invention cannot be limited thereby.

[0034] The raw materials used in the present invention are all conventional commercially available products without special instructions; the methods used in the present invention are all conventional methods in the art without special instructions.

[0035] A Pediococcus acidilactici with anti-inflammatory effect, the name of the Pediococcus acidilactici is HAO2018, the classification name is Pediococcus acidilactici, the preservation number is: CGMCC No. 16658, the preservation date: October 30, 2018, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, the preservation unit: China General Microbiological Culture Collection Center.

[0036] Preferably, the Pediococcus acidilactici has anti-inflammatory ability. Through an in vitro verification model constructed by inducing mouse RAW264.7 macrophages to overproduce nitric oxide (NO) with cell lipopolysaccharide (LPS), the NO production inhibitory rates of the supernatant and cell lysate of the 5mg / mL strain fermentation broth reach 60% and 56% respectively, verifying that the supernatant and cell lysate of the Pediococcus acidilactici fermentation broth can inhibit the level of NO.

[0037] Preferably, the anti-inflammatory oral liquid containing Dictyophora indusiata and Pediococcus acidilactici has stronger anti-inflammatory ability than the Dictyophora indusiata oral liquid without probiotic fermentation. Through an in vitro verification model constructed by inducing mouse RAW264.7 macrophages to overproduce nitric oxide (NO) with cell lipopolysaccharide (LPS), the NO production inhibitory rate of the anti-inflammatory oral liquid reaches 61%, verifying that the anti-inflammatory oral liquid containing Dictyophora indusiata and probiotics can inhibit the level of NO.

[0038] Example 1: Cultivation of the strain

[0039] After inoculating Pediococcus acidilactici on MRS solid medium and culturing anaerobically at 37°C for 48h, the colony morphology was observed to be white, round, with a smooth and moist surface, and the edges were neat and raised.

[0040] Example 2: Determination of the acid tolerance of Pediococcus acidilactici HAO2018

[0041] The lactic acid bacteria were activated three times and placed in an anaerobic incubator at 37°C for overnight culture. The concentration of its bacterial cells was diluted to 5×108 CFU / mL and transferred to MRS medium with different pH values, where the pH values were 2.0, 3.0, and 4.0 respectively. The bacterial solutions with different pH values were placed in 96-well plates, and six parallel wells were set for each experimental group. A negative control was required, and the negative control was MRS with a pH value of 7. It was placed in an anaerobic incubator at 37°C for 4 hours. Add 20 μL of MTT (5 mg / mL) and place it in the anaerobic incubator for 4 hours. Measure the absorbance value (Aexperimental group) of each well at 490 nm with an enzyme-linked immunosorbent assay detector and compare it with the absorbance value (Acontrol group) of the negative control group to determine the survival rate. The survival rate calculation formula is as follows:

[0042] Survival rate (%) = (Aexperimental group) / (Acontrol group) × 100%

[0043] The results were as Figure 1 shown. The survival rate of Pediococcus acidilactici HAO2018 under pH 4 conditions was 56.67 ± 1.66%, indicating good acid tolerance.

[0044] Example 3: Determination of the bile salt tolerance of Pediococcus acidilactici HAO2018

[0045] The lactic acid bacteria were activated three times and placed in an anaerobic incubator at 37°C for overnight culture. The concentration of its bacterial cells was diluted to 5×10 8 CFU / mL and transferred to MRS medium with different bile salt concentrations, where the bile salt concentrations were 0.1% (w / v), 0.2% (w / v), and 0.3% (w / v). The bacterial solutions treated with different bile salt concentrations were placed in 96-well plates, and six parallel wells were set for each experimental group. A negative control was required, and the negative control was MRS with a pH value of 7. It was placed in an anaerobic incubator at 37°C for 4 hours. Add 20 μL of MTT (5 mg / mL) and place it in the anaerobic incubator for 4 hours. Measure the absorbance value (Aexperimental group) of each well at 490 nm with an enzyme-linked immunosorbent assay detector and compare it with the absorbance value (Acontrol group) of the negative control group to determine the survival rate. The survival rate calculation formula is as follows:

[0046] Survival rate (%) = (Aexperimental group) / (Acontrol group) × 100%

[0047] The results were as Figure 3 shown. The survival rate of Pediococcus acidilactici HAO2018 under 0.3% bile salt conditions was 51.39% ± 1.38, indicating good bile salt tolerance.

[0048] Example 4: Effect of Pediococcus acidilactici HAO2018 on NO secretion of LPS-induced RAW264.7 cells

[0049] (1) The production of NO was indirectly evaluated by measuring the nitrite level. RAW264.7 cells were pre-incubated with the supernatant of Pediococcus acidilactici fermentation broth (0, 0.25, 1, and 5 mg / mL) and the cell lysate of Pediococcus acidilactici (0, 0.25, 1, and 5 mg / mL) for 1 hour, and then co-treated with 100 ng / mL LPS at 37 °C for 24 hours. Subsequently, 100 μL of each collected medium was combined with the same volume of Griess reagent (1% sulfanilamide, 0.1% N-(1-naphthyl)ethylenediamine dihydrochloride, and 5% phosphoric acid) and incubated at room temperature for 10 minutes. The absorbance was measured using a multi-functional microplate reader at 540 nm. The homogeneous tissue sample of the mixture was diluted four-fold with distilled water, and 1 / 20 volume of zinc sulfate for deproteinization (300 mg / mL) was added to a final concentration of 15 mg / mL. After centrifugation at 10,000 g for 5 minutes at room temperature, 100 μL of the supernatant was added to a microtiter plate, and then 100 μL of Griess reagent was added. After color development at room temperature for 10 minutes, the absorbance was measured using a multi-functional microplate reader at 540 nm. By using a standard curve generated with sodium nitrite, the concentration of nitrite was measured by the absorbance at 540 nm.

[0050] Inhibition rate (%) = (1 - (Aexperimental group) / (Acontrol group)) × 100%

[0051] The results are as Figure 3 、 Figure 4 、 Figure 5 and Figure 6 shown. The supernatant and cell lysate of the fermentation broth of Pediococcus acidilactici HAO2018 can inhibit the level of NO. The NO production inhibition rates of the supernatant and cell lysate of the strain at 5 mg / mL reached 60% and 56% respectively, verifying that the supernatant and cell lysate of Pediococcus acidilactici can inhibit the level of NO. It shows that Pediococcus acidilactici has good anti-inflammatory effects.

[0052] Example 5:

[0053] A compound probiotic anti-inflammatory oral liquid containing Dictyophora indusiata in the embodiments of the present invention is prepared as follows:

[0054] (1) 47 kg of Dictyophora indusiata was cleaned and disinfected, and then homogenized to obtain Dictyophora indusiata pulp.

[0055] (2) 0.15 kg of pectinase was added to the Dictyophora indusiata pulp obtained in step (1), and stirred at a stirring speed of 50 r / min at 25 °C for 1 h.

[0056] (3) 8 kg of fructose, 3 kg of honey, and 0.3 kg of citric acid were added to the Dictyophora indusiata pulp obtained in step (2) to adjust the sugar content and flavor.

[0057] (4) The Dictyophora indusiata pulp obtained after step (3) is sterilized at 115 °C for 15 min under a pressure of 700 Mpa.

[0058] (5) The Dictyophora indusiata pulp completed in step (4) is mixed with 470 kg of sterile water in a fermenter, and Pediococcus acidilactici at an inoculation amount of 3% is inoculated at 10 8 cfu / mL and fermented at 37 °C for 12 h.

[0059] (6) After the fermentation in step (5) is completed, 0.12 kg of carrageenan is added to the fermenter and stirred evenly.

[0060] (7) The compound probiotic anti-inflammatory oral liquid containing Dictyophora indusiata prepared in step (6) is refrigerated in a refrigerator at 0-4 °C, and the shelf life of the product at 0-4 °C is 14 days.

[0061] Example 6: Effect of the compound probiotic anti-inflammatory oral liquid containing Dictyophora indusiata on NO secretion of RAW264.7 cells induced by LPS

[0062] RAW264.7 cells are pre-incubated with the Dictyophora indusiata oral liquid without fermentation by Pediococcus acidilactici in Example 5 and the compound probiotic anti-inflammatory oral liquid containing Dictyophora indusiata in Example 5 for 1 hour, and then co-treated with 100 ng / mL LPS at 37 °C for 24 hours. Subsequently, 100 μL of each collected culture medium is combined with the same volume of Griess reagent (1% sulfanilamide, 0.1% Naphthylethylenediamine dihydrochloride and 5% phosphoric acid) and incubated at room temperature for 10 minutes. The absorbance is measured at 540 nm using a multifunctional microplate reader. The homogeneous tissue sample of the mixture is diluted four times with distilled water, and 1 / 20 volume of zinc sulfate deproteinization (300 mg / mL) is added to a final concentration of 15 mg / mL. After centrifugation at 10,000 g for 5 minutes at room temperature, 100 μL of the supernatant is added to a microtiter plate, and then 100 μL of Griess reagent is added. After color development at room temperature for 10 minutes, the absorbance is measured at 540 nm using a multifunctional microplate reader. By using a standard curve generated with sodium nitrite, the concentration of nitrite is measured by the absorbance at 540 nm.

[0063] Inhibition rate (%) = (1 - (A experimental group) / (A control group)) × 100%

[0064] The results are as Figure 7 and Figure 8As shown, the dictyophora indusiata oral liquid without fermentation by pediococcus acidilactici can significantly inhibit the production of NO by RAW264.7 cells. Compared with the dictyophora indusiata oral liquid without fermentation by pediococcus acidilactici, the amount of NO produced by RAW264.7 cells in the compound probiotic anti-inflammatory oral liquid containing dictyophora indusiata in Example 5 is significantly reduced. The inhibition rate of NO production by the dictyophora indusiata oral liquid without fermentation by pediococcus acidilactici is 32.5%, while the inhibition rate of NO synthesis by the compound probiotic anti-inflammatory oral liquid containing dictyophora indusiata reaches 61%. This shows that the dictyophora indusiata oral liquid without fermentation by pediococcus acidilactici itself has a good anti-inflammatory effect. After fermentation by pediococcus acidilactici HAO2018, the obtained anti-inflammatory oral liquid has a better anti-inflammatory effect than the dictyophora indusiata oral liquid without fermentation by pediococcus acidilactici.

[0065] Although embodiments of the present invention have been disclosed for illustrative purposes, those skilled in the art will understand that: within the spirit and scope of the present invention and the appended claims, various substitutions, changes, and modifications are possible. Therefore, the scope of the present invention is not limited to the content disclosed in the embodiments.

Claims

1. A Pediococcus acidilactici with anti-inflammatory properties. The Pediococcus acidilactici is named HA02018, classified as Pediococcus acidilactici, deposited under the accession number CGMCC No. 16658 on October 30, 2018, at the General Microbiology Center of the China Committee for Culture Collection of Microorganisms, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

2. The Pediococcus acidilactici with anti-inflammatory effect according to claim 1, characterized in that: The Pediococcus acidilactici has strong bile salt tolerance and acid tolerance.

3. The Pediococcus acidilactici with anti-inflammatory effect according to claim 1, characterized in that: The Pediococcus acidilactici has anti-inflammatory ability. Through an in vitro verification model constructed by inducing excessive synthesis of nitric oxide (NO) in mouse RAW264.7 macrophages with lipopolysaccharide (LPS), the NO production inhibition rates of the supernatant and cell lysate of the strain fermentation broth at 5 mg / mL reached 60% and 56% respectively, verifying that the supernatant and cell lysate of the Pediococcus acidilactici fermentation broth can inhibit the level of NO.

4. A preparation method of a compound probiotic anti-inflammatory oral liquid containing dictyophora indusiata, characterized in that, It includes the following steps: (1) Wash and disinfect the dictyophora, and then homogenize it to obtain dictyophora pulp. (2) Add pectinase to the homogenized dictyophora pulp to decompose insoluble substances. (3) Add fructose, honey, and citric acid to the dictyophora pulp after decomposing insoluble substances to adjust the sugar content and flavor. (4) Sterilize the dictyophora pulp after adjusting the sugar content and flavor. (5) Inoculate the sterilized dictyophora pulp with Pediococcus acidilactici and ferment. (6) Add carrageenan to the fermentation broth to adjust the consistency and prepare a compound probiotic anti-inflammatory oral liquid containing dictyophora. (7) Store the prepared compound probiotic containing dictyophora at low temperature.

5. The preparation method of the anti-inflammatory oral liquid of compound probiotics containing dictyophora indusiata according to claim 4, characterized in that: A compound probiotic anti-inflammatory oral liquid containing dictyophora, including the following components in parts by weight: 45 - 50 of dictyophora, 5 - 10 of fructose, 2 - 5 of honey, 0.1 - 0.5 of citric acid, 0.1 - 0.15 of carrageenan, 0.08 - 0.2 of pectinase, and 450 - 500 of sterile water.

6. The preparation method of the anti-inflammatory oral liquid of compound probiotics containing dictyophora indusiata according to claim 4, characterized in that: In the step (5), the inoculation amount of Pediococcus acidilactici at 10 8 cfu / mL accounts for 1.8%-3.8% of the total mass of the mixture of dictyophora indusiata pulp and sterile water. The fermentation conditions are as follows: at 30℃-40℃, ferment for 10-14h.

7. The preparation method of the anti-inflammatory oral liquid of compound probiotics containing dictyophora indusiata according to claim 4, characterized in that: In step (7), the prepared compound probiotic anti-inflammatory oral liquid containing dictyophora is refrigerated in a refrigerator at 0 - 4°C, and the shelf life of the product at 0 - 4°C is 14 days.

8. The compound probiotic anti-inflammatory oral liquid containing dictyophora indusiata according to claim 4, characterized in that: It has stronger anti-inflammatory ability than the dictyophora oral liquid without probiotic fermentation. Through an in vitro verification model constructed by inducing excessive synthesis of NO in mouse RAW264.7 macrophages with lipopolysaccharide (LPS), the NO production inhibition rate of the compound probiotic anti-inflammatory oral liquid containing dictyophora reaches 61%, verifying that the compound probiotic anti-inflammatory oral liquid containing dictyophora can inhibit the level of NO.

9. A compound probiotic anti-inflammatory oral liquid containing dictyophora indusiata, characterized in that It is prepared by using the preparation method described in any one of claims 4 - 8.

Images